See analyst estimates and all valuation multiples for Regenerative Medicine
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $104B | 8.8x | 22.3x | |
| $9.4B | 3.0x | 12.7x | |
| $5.0B | 13.6x | 34.3x | |
| $4.1B | 144.0x | -7.2x | |
| $3.6B | 9.8x | 23.0x | |
| $3.0B | 4.9x | 35.2x | |
| $2.6B | 735.7x | -156.3x | |
| $2.0B | 46.8x | -42.9x | |
| $1.8B | 69.1x | -11.0x | |
| $1.8B | 6.5x | 25.7x | |
| $1.5B | 34.6x | -3.5x | |
| $1.5B | n/a | n/a | |
| $1.3B | n/a | -52.1x | |
| $1.1B | 4.9x | 38.8x | |
| $998M | 16.3x | -2.2x | |
| $989M | 2.5x | 10.1x | |
| $745M | 16.4x | 133.6x | |
| $635M | 1.3x | 15.6x | |
| $451M | 13.7x | 27.4x | |
| $407M | 46.5x | -11.7x | |
| $306M | 269.2x | n/a | |
| $274M | 86.7x | n/a | |
| $209M | n/a | n/a | |
| $200M | n/a | n/a | |
| $193M | 26.9x | -37.1x | |
| $176M | 37.2x | -1.8x | |
| $174M | 6.7x | 14.3x | |
| $171M | 3.1x | 44.4x | |
| $138M | 359.1x | -0.6x | |
| $115M | n/a | n/a | |
| $113M | 1.0x | 28.2x | |
| $97.2M | 259.4x | -0.6x | |
| $64.6M | n/a | n/a | |
| $59.2M | 2.4x | -4.4x | |
| $57.2M | n/a | -4.6x | |
| $56.1M | 630.9x | n/a | |
| $54.8M | 0.2x | n/a | |
| $43.5M | n/a | n/a | |
| $35.5M | 7.4x | -4.4x | |
| $32.6M | n/a | n/a | |
| $25.0M | 4.1x | n/a | |
| $20.6M | 2.8x | n/a | |
| $18.4M | n/a | n/a | |
| $8.4M | 5.9x | n/a | |
| -$35.3M | n/a | n/a | |
| -$90.6M | -1.0x | 0.7x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Regenerative Medicine